

24. Bölüm

COVID-19 PANDEMİSİNDE GASTROİNTESTİNAL SİSTEM TÜMÖRLERİNDE HASTA YÖNETİMİ

Emel MUTLU¹

GİRİŞ

İlk defa Aralık 2019'da Çin'in Wuhan eyaletinde tespit edilen ve şiddetli akut solunum sendromuna neden olan Koronavirüs Hastalığı-2019 (COVID-19), ciddi bir küresel sağlık sorunu haline geldi ve Mart 2020'de Dünya Sağlık Örgütü (DSÖ) tarafından pandemi ilan edildi. COVID-19 pandemisi sürecinde kanser hastaları hem enfeksiyon bulaşma riski, hem de ağır enfeksiyon geçirip ciddi olay geliştirme riski yüksek bir hasta grubunu oluşturmaktadır. Bu süreçte kanser hastalarının tedavileri riske atılmamalıdır ancak, tedavi devam ederken enfeksiyon riski de en aza indirilmelidir. Kanser hastalarında tedavinin aciliyeti, pandemi sırasında artmış riske karşı dengelenmeli ve tedavinin ertelenmesi durumunda ortaya çıkabilecek olumsuz etkiler her hasta için ayrı olarak değerlendirilmelidir. Özellikle küratif tedavi edilen hastaların tedavisinin kesintiye uğramasını en aza indirmek için gerekli stratejiler uygulanmalıdır. Bu veriler ışığında, gastrointestinal sistem (GİS) kanserli hastaların tanı ve tedavi sürecinde pandemi döneminde hastalara mümkün olan en iyi onkolojik tedaviyi sağlamak amacıyla standart tedavilerin risk ve faydaları yeniden gözden geçirilmiştir ve güncel öneriler derlenmiştir.

COVID-19 ve Kanser Hastaları

Kanser hastaları, kanserin kendisinin ya da tedavisinin yol açtığı sistemik immünespresif durum nedeniyle enfeksiyona kanser olmayanlardan daha yatkın-

¹ Uzm. Dr. Emel MUTLU, Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji BD., emelmutlu@erciyes.edu.tr

KAYNAKLAR

1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *The lancet oncology*. 2020;21(3):335-7.
2. Eliakim-Raz N, Vinograd I, Trestioreanu AZ, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. *Cochrane Database of Systematic Reviews*. 2013(10).
3. Burki TK. Cancer guidelines during the COVID-19 pandemic. *The Lancet Oncology*. 2020;21(5):629-30.
4. Barbieri L, Talavera Urquijo E, Parise P, Nilsson M, Reynolds JV, Rosati R. Esophageal oncologic surgery in SARS-CoV-2 (COVID-19) emergency. *Diseases of the Esophagus*. 2020;33(5):doaa028.
5. Mariette C, Markar S, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, et al. Health-related quality of life following hybrid minimally invasive versus open esophagectomy for patients with esophageal cancer, analysis of a multicenter, open-label, randomized phase III controlled trial: the MIRO trial. *Annals of surgery*. 2020;271(6):1023-9.
6. McLoughlin JM, Lewis JM, Meredith KL. The impact of age on morbidity and mortality following esophagectomy for esophageal cancer. *Cancer Control*. 2013;20(2):144-50.
7. Tuech JJ, Gangloff A, Di Fiore F, Michel P, Brigand C, Slim K, et al. Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic. *Journal of visceral surgery*. 2020;157(3):S7-S12.
8. Wilson MSJ, Blencowe NS, Boyle C, Knight SR, Petty R, Vohra RS, et al. A modified Delphi process to establish future research priorities in malignant oesophagogastric surgery. *The Surgeon*. 2020;18(6):321-6.
9. Griffiths EA, Alwan LM, Bachashvili K, Brown A, Cool R, Curtin P, et al. Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. *Journal of the National Comprehensive Cancer Network*. 2020;1(aop):1-4.
10. Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *The Lancet*. 2019;393(10184):1948-57.
11. Finley C, Prashad A, Camuso N, Daly C, Aprikian A, Ball CG, et al. Guidance for management of cancer surgery during the COVID-19 pandemic. *Canadian Journal of Surgery*. 2020;63(2 Suppl 1):S2.
12. Zhao B, Lv W, Lin J. Delaying adjuvant chemotherapy in advanced gastric cancer patients: Risk factors and its impact on survival outcome. *Current Problems in Cancer*. 2020;44(6):100577.
13. Tchelebi LT, Haustermans K, Scorsetti M, Hosni A, Huguet F, Hawkins MA, et al. Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. *Radiotherapy and Oncology*. 2020;148:194-200.
14. Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E. A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. *BMC cancer*. 2013;13(1):1-8.
15. Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, et al. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID-19 pandemic. *Radiotherapy and Oncology*. 2020;148:213-5.
16. Siavashpour Z, Taghizadeh-Hesary F, Rakhsha A. Recommendations on management of locally advanced rectal cancer during the COVID-19 pandemic: an Iranian Consensus. *Journal of Gastrointestinal Cancer*. 2020:1-5.
17. Seymour MT, Morton D, International FTI. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

American Society of Clinical Oncology; 2019.

18. André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial. *Journal of clinical oncology*. 2018;36(15):1469-77.
19. Waisberg F, Enrico D, Angel M, Chacón M. Cancer treatment adaptations in the COVID-19 era. *JCO oncology practice*. 2020;16(6):305.
20. Pang J, Xu F, Aondio G, Li Y, Fumagalli A, Lu M, et al. Efficacy and tolerability of bevacizumab in patients with severe COVID-19. *Nature communications*. 2021;12(1):1-10.
21. Lee LYW, Cazier JB, Starkey T, Turnbull CD, Team UKCCMP, Kerr R, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *The Lancet*. 2020;395(10241):1919-26.
22. <https://www.esmo.org/guidelines/gastrointestinal-cancers/gastrointestinal-cancers-colorectal-cancer-crc-in-the-COVID-19-era>